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Abstract
Pancreatic carcinoma is a leading cause of cancer-related death. Reduction of the diagnostic delay is mandatory. Adrenomedullin (AM) is overexpressed in pancreatic 
cancer. A case-control study including 12 patients with pathological diagnosis of pancreatic carcinoma and 10 healthy controls was conducted at our Institution. 
Blood samples were obtained at the time of hospitalization and post-operatively for cases. Controls’ samples were obtained from healthy volunteers. AM was 
measured by using enzyme immunoassay method. AM showed significant increase in pancreatic carcinoma patients vs controls (4.51 ng/ml vs 1.91 ng/ml, p value 
= 0.04) regardless of tumor stage, differentiation, resecability/unresecability, diabetes. A cut-off of 1.75 ng/ml reaches a sensibility of 83% and a specificity of 70% 
(p value = 0.0147; CL 95%; AUC 0.767). The increase of AM didn’t correlate with the increase of other common tumor markers (CA 19-9 and CEA), nor direct 
bilirubin. These data confirm the utility of studying the role of AM in pancreatic cancer, in order to achieve an early diagnosis in high risk populations.
Introduction
Pancreatic carcinoma (PaC) is the fourth leading cause of cancer-
related death in the western World [1] and its incidence is increasing 
in sexes (+ 0.8% per year males; + 2.0% per year females) [2]. Up to 
now surgical resection is the only curative option for those patients 
[3]. Overall survival at 5-years for resected patients reaches a 43% rate 
[4] compared to a global 5-years survival rate of 5% 3. However, only 
20% of patients are diagnosed with a resectable disease, and a complete 
resection (R0) is achieved in less than 10% [5]. Late clinical signs and 
absence of specific tests are responsible for the delay in the diagnosis 
of PaC [3]. Currently, CA 19-9 is the only marker acknowledged 
worldwide for PaC diagnosis [2,6], and the main limitations to its use 
are low specificity [6-8] and late increase on disease progression [2]. 
Adrenomedullin (AM) is up-reguleted in pancreatic cancer [9] and 
it is investigated as a possible diabetogenic mediator [9]. Both cancer 
cells and neighboring pancreatic tissue show AM overexpression 
independently from the stage of the neoplastic disease [9]. The aim 
of this study was to evaluate serum AM levels with cytological and/or 
histological diagnosis of PaC compared to non-cancer controls. This 
represents the validation phase of a larger prospective study that aims 
to evaluate the role of AM in the early detection of PaC in a high risk 
population: new-onset diabetic patients [ClinicalTrials.gov Identifier: 
NCT02456051].
Materials and methods
From November 2013 through August 2014, 16 patients presenting 
with suspect of pancreatic carcinoma to the Department of General 
Surgery of St Andrea University Hospital in Rome were evaluated. 
Patients were enrolled in the study according to the following criteria: 
pancreatic adenocarcinoma confirmed by cytological or histological 
sample; written informed consent provided by each patient; age 18-90. 
Exclusion criteria were: other than ductal adenocarcinoma pancreatic 
neoplasm; other synchronous malignancies; post operative sepsis 
or renal failure signs. The main characteristics of the patients are 
summarized in Table 1. 10 non-cancer volunteers were enrolled in the 
study as controls, and this population is homogeneous to the cases in 
terms of age and sex. Their characteristics are summarized in Table 2. 
Blood samples were obtained at the time of hospitalization and, 
when resection was feasible, post-operatively in 7th post-operative day. 
Each blood sample was centrifuged (4000 RPM for 10 minutes), divided 
into 1.5 ml aliquots and stored up at -18°C. AM was measured by using 
commercially available EIA method (Adrenomedullin (Human) EIA 
Kit, Phoenix Pharmaceuticals, Inc.Mountain View, CA,USA). The 
intra- and inter-assay coefficients were 5.1% and 12%, respectively.
For statistical analysis Excel program (Microsoft®) has been utilized. 
T-test was applied to compare serum levels of AM in the study groups. 
Comparisons were: PaC patients vs non-cancer controls; among the 
PaC population, earlier stages vs later stages, more differentiated vs 
less differentiated, resectable vs unresectable, diabetics vs no diabetics; 
among the operated population, preoperative levels vs postoperative 
levels. Linear regression and Pearson coefficient were evaluated to 
detect possible correlation between serum levels of AM and CA 19-9, 
CEA, direct bilirubin. Correlations between AM and preoperative FPG 
and AM and diabetes duration were analyzed too. 
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P value was assumed significant when < 0.05. ROC curve for AM 
was designed to detect the serum cut-off concentration with the best 
sensitivity and specificity. The study was conducted in the respect of the 
principles of Helsinki declaration [10].
Results
12 out of 16 patients were included in the study after histological 
diagnosis of pancreatic adenocarcinoma. The other 4 were excluded for 
different histological findings. 6 patients underwent a complete tumor 
resection while the remaining 6 patients received palliative care or 
chemotherapy regimens. Mean serum AM level in PaC patients at the 
time of hospitalization was 4.51 ng/ml (range 0.04 – 9.16 ng/ml, SD 
3.17). Resected patients had a preoperative mean serum AM level of 
4.94 ng/ml(range 0.04 – 9.16 ng/ml, SD 3.56) and a postoperative mean 
serum AM level was 2.13 ng/ml (range 0.47 – 3.77 ng/ml, SD 1.60). 
The mean decrease of serum AM was 2.8 ng/ml (range -0.43 – 8.11, 
SD 3.14) but wasn’t statistically significant (p = 0.12). Serum AM was 
significantly increased in PaC patients than in controls (4.51 ng/ml vs 
1.91 ng/ml; p = 0.04) (Table 3 and 4). All other comparisons are shown 
in Table III. None of the correlations investigated with CA19.9, CEA, 
bilirubin, FPG and diabetes duration was significant (Table 4 and 5). 
ROC curve pointed out that a cut-off of 1.75 ng/ml AM had a sensitivity 
of 83% and a specificity of 70% (p value = 0.0147; CL 95%; AUC 0.767) 
to distinguish cases from controls (Figure 1).
Discussion
Diagnostic delay is responsible for the high mortality of PaC, which 
 
Figure 1. Adrenomedullin (AM) ROC curve. Cut-off 1.75 ng/ml AM (sensitivity 83%, 
specificity 70%, p val Adrenomedullin ue 0.0147, CL 95%, AUC 0.767).
Age –years old- Median (range) 68 (45 – 77)
Sex - No (%) of males 7 (58.3)
Smokers - No (%) 6 (50)
Comorbidities - No (%)
- Cardiovascular
- Respiratory
- Other
9 (75)
3 (25)
5 (41.7)
ADA criteria for diabetes responding patients- No (%) 6 (50)
Time from diabetes diagnosis to cancer diagnosis –months-  
Median (range) 66 (1 – 360)
Oncomarkers > reference values No (%)
- CA 19-9
- CEA
7 (58.3)
5 (41.7)
Tumor localization No (%)
- Head
- Body - tail
- Head and body - tail
10 (83.3)
1 (8.3)
1 (8.3)
Clinical Stage No (%)
- I 
o IA
o IB
- II
o IIA
o IIB
- III
- IV
1 (8.3)
0 (0)
1 (8.3)
4(33.3)
2 (17)
4 (33.3)
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4
1
0
5
0
pNa - No (%)
- Nx- N
0- N1
0
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4
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- Mo- M1
5
1
R – No (%)*
- R
0- R1- R2
6
0
0
G - No (%)*
- G1- G2- G3
3
2
1
a pTNM was evaluated in resectable patients (6 of 12)
Table 1. Characteristics of the patients affected by pancreatic adenocarcinoma.
Age –years old- Median (range) 55 (25 – 90)
Sex – N. (%) of males 6 (60)
Smokers N. (%) 6 (60)
Diabetes N. (%) 1 (10)
Comorbidities N. (%)
- Cardiovascular
- Respiratory
- Other 
3 (30)
0 (0)
3 (30)
Table 2. Characteristics of noncancer controls.
Mean (SD) Mean (SD) P value
PaC patients VS Controls 4.51 ng/ml (3.17) 1.91 ng/ml (2.20) 0.04
Stage I-II VS Stage III-IV 5.05 ng/ml (3.97) 4.96 ng/ml (2.51) 0.86
G1 VS G2 6.68 ng/ml (3.86) 2.61ng/ml (3.63) 0.93
Resectable VS Unresectable 4.94 ng/ml (3.56) 4.75 ng/ml (2.80) 0.93
Preoperative VS Postoperative 4.94 ng/ml (3.56) 2.13 ng/ml (1.60) 0.12
Diabetic VS No diabetic 5.45 ng/ml (3.10) 3.57 ng/ml (3.22) 0.33
Table 3. Serum AM levels mean (and Standard Deviation) of the compared groups and 
respective p value.
Pearson coefficient (R2 and p value)
AM – CA 19-9 0.345 (0.119; >0.2)
AM – CEA -0.28 (0.08; > 0.5)
AM – Direct Bil. 0.26 (0.07; >0.2)
Table 4. Correlation between serum AM levels and serum CA 19-9, CEA and direct 
bilirubin levels.
Pearson coefficient (R2 and p value)
AM – FPG 0.28 (0.08; >0.2)
AM – diabetes duration 0.57 (0.33; >0.2)
Table 5.  Correlation between serum AM levels and FPG and duration of diabetes.
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almost coincides with its incidence [1,3]. PaC-related symptoms are 
late-onset in the natural history of the disease [3], therefore early serum 
markers are needed. Unfortunately, the ones currently available are 
related to late stages, and so are unuseful in detecting a resectable disease 
[2]. This urge to seek new diagnostic markers led us to investigate the 
role of Adrenomedullin in PaC. The interest for AM arises from recent 
studies that investigated PaCDM mediators [12-14]. AM is a 52-amino 
acid peptide discovered in 1993 [15]. It is physiologically produced 
by human organism [16] but its secretion increases in multiple 
pathological conditions, such as endothelial damage, heart failure, 
hypertension, renal failure, sepsis and hypoxia [17,18]. Physiologically 
AM is recognized as a regulator of the pancreatic secretion [14,19,20], 
while in pancreatic cancer, it is overexpressed in both neoplastic and 
peritumoral tissues. Circulating levels are increased too [9]. Recently 
new-onset diabetes mellitus has been investigated as a possible early 
manifestation of pancreatic cancer (PaCDM). 50% of patients affected 
by PaC are diabetic, 70% of whom were diagnosed for being diabetic 
less than 2 years before tumor diagnosis [12]. Moreover, PaCDM is 
an early manifestation of the disease and develops when the tumor is 
resectable in 55% – 65% of the cases [21]. In our population AM did 
not show any correlation with DM presence. We might hypothesize 
that AM is over-expressed in all PaC patients and that only subjects 
likely to develop diabetes reveal the effects of β-cell dysfunction. In this 
study we included only pancreatic ductal adenocarcinomas, which is 
the most frequent histological type of pancreatic carcinoma to avoid 
confounding factors deriving from heterogeneity of histology [3]. In 
our population serum AM showed a significant increase in PaC patients 
but do not correlate with tumor stage, differentiation or resectability. 
AM levels do not show any relation neither with pre-operative FPG or 
length of diabetes. Those characteristics could configure AM as an early 
tumor marker: its stage-independence makes it a promising diagnostic 
tool. Moreover, AM showed a decreasing trend after resection, even if 
not in a statistically significant way. We can hypothesize that dosing the 
peptide later than the 7th pod would have allowed a better washout and, 
consequently lower AM levels. These preliminary data confirm the tight 
relationship between Adrenomedullin and Pancreatic Cancer. Further 
studies are needed to investigate the role of AM as early diagnostic tool 
in high risk populations.
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